Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 2Colonic Neoplasms 2Thyroid Neoplasms 1Polycystic Ovary Syndrome 1Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pain 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Hypothyroidism 1Hyperphagia 1Hematologic Neoplasms 1Goiter 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Cancer Pain 1Breast Neoplasms 1

Interventions

Morphine 11Oxycodone 8Fentanyl 6nabiximols 5Methadone 4Hydromorphone 4Acetaminophen 3Transcutaneous Electric Nerve Stimulation 2Tapentadol 2Naloxone 2Lidocaine 2Buprenorphine 2Acupuncture Therapy 2tanezumab 1resiniferatoxin 1oxycodone naloxone combination 1fulranumab 1cannabichromene 1alvimopan 1Water 1Ultracet 1Transcranial Direct Current Stimulation 1Tramadol 1Therapeutic Touch 1Telemedicine 1Tablets 1Surveys and Questionnaires 1Sugars 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cancer Pain × Glucose × Clear all
NCT01384877 2019-07-12

Subcutaneous Lidocaine For Cancer-Related Pain

British Columbia Cancer Agency

Phase 2/3 Completed
33 enrolled 16 charts

Cancer Pain, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡